KEY TAKEAWAYS
- The study aimed to design a non-invasive diagnostic tool for early detection of OC.
- Venient Sx Ovarian Basic shows promising preliminary evidences for early OC diagnosis, further investigation is ongoing.
Ovarian cancer (OC) ranks 7 among women’s cancers and 8 in terms of female cancer-related deaths. Despite its relatively low incidence, its impact is profoundly high due to later detection and limited treatment options thus being known as ‘silent killer’ because of its non-specific symtomps. The delayed diagnosis leads to metastasis thus making it challenging for oncologists to detect it in early stages.
José Diego Santotoribio and Sergio J. Calleja Freixes attempted to design a novel diagnostic tool for early detection of OC.
This study introduced the Venient Sx Ovarian Basic, an innovative non-invasive test designed for early detection of OC. This diagnostic tool aimed to accurately identify ovarian cancer even in its early stages, before the onset of symptoms when treatment is most likely to be effective.
Results indicated that Venient Sx Ovarian Basic, evaluated with 9,324 individuals, demonstrated high diagnostic performance for OC screening with sensitivity and specificity values of 0.97 and 0.93 respectively. Which established its effectiveness in distinguishing between healthy and OC individuals.
The estimated area under the receiver operating characteristic (AUROC) curve was 0.92, indicating an excellent overall discriminatory ability. The positive predictive value (PPV) of 0.93 advocated that among those testing positive, 93% truly had OC, while the negative predictive value (NPV) of 0.97 indicated that 97% of those testing negative were correctly identified as cancer-free.
These findings presented Venient Sx Ovarian Basic as a robust non-invasive test with strong reliability in early detection, potentially improving outcomes through timely intervention.
The study concluded that the innovative non-invasive blood-based biomarker algorithm, Venient Sx Ovarian Basic, showed potential for effective OC screening. The research team plans to conduct a comprehensive parallel study incorporating additional ovarian analytes to further enhance the sensitivity (Se) of the test.
The goal is to provide physicians with a screening tool that minimizes false negatives (FN), thereby improving early detection rates and potentially leading to better patient outcomes in the management of OC.
The study was funded by Kience Inc..
Source: https://cslide.ctimeetingtech.com/gynae24hybrid/attendee/confcal_1
Santotoribio J D and Freixes S J C, (2024). “An innovative evidence-based laboratory medicine (EBLM) test to help doctors in the screening of ovarian cancer.” Presented at ESMO-GC 2024, (Abstract 6P)
